Kiora Pharmaceuticals vs Talphera
KPRX and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KPRX and TLPH compare
Talphera is the larger company, worth 8.6 times as much as Kiora Pharmaceuticals ($47.0M against $5.4M).
Kiora Pharmaceuticals scores higher on the StockData Score (6 against 5 for Talphera), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KPRX | TLPH |
|---|---|---|
| Size and price | ||
| Market cap | $5.4M | $47.0M |
| Share price | $1.23 | $0.906 |
| Change, 1 year | −46.6% | −29.8% |
| Change, 5 years | −99.8% | −93.7% |
| Beta (5Y) | 0.80 | 0.61 |
| Employees | 3,500 | 12 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× (better) | 4.4× |
| FCF yield | −145% | – |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −65.1% |
| Profitability | ||
| Return on equity | −67.7% (better) | −98.1% |
| Return on invested capital | −1063% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.91 (better) | 3.19 |
| Altman Z-score | −10.67 (better) | −28.10 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 25.0% | 54.4% |
| Held by insiders | 3.0% | 46.8% |
| Insider net buying, 12 months | – | $304K |
| Short interest, % of float | – | 4.4% |
Go deeper
- KPRX stock overview
- KPRX income statement
- KPRX valuation and score
- TLPH stock overview
- TLPH income statement
- TLPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.